Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2023-173991

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Eytan M. Stein, Farhad Ravandi, Stefan Faderl, Roland B. Walter, Anjali S. Advani, Daniel J. DeAngelo, Tibor J. Kovacsovics, Anand Jillella, Dale Bixby, Moshe Y. Levy, Megan M. O’Meara, Phoenix A. Ho, Jenna Voellinger, Anthony S. Stein

Blood (2018) 132 (11): 1125–1133.

https://doi.org/10.1182/blood-2018-03-841171

Published: 2018

Journal Articles

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Eytan M. Stein, Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani, Jeffrey E. Lancet, Farhad Ravandi, Tibor Kovacsovics, Daniel J. DeAngelo, Dale Bixby, Stefan Faderl, Anand P. Jillella, Phoenix A. Ho, Megan M. O’Meara, Baiteng Zhao, Charles Biddle-Snead, Anthony S. Stein

Blood (2018) 131 (4): 387–396.

https://doi.org/10.1182/blood-2017-06-789800

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Amir T. Fathi, MD, Harry P Erba, MD PhD, Jeffrey E Lancet, MD, Eytan M Stein, Roland B. Walter, MD PhD MS, Daniel J. DeAngelo, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Farhad Ravandi, MD, Anjali S. Advani, MD, Dale Bixby, MD PhD, Tibor J. Kovacsovics, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, Anthony S. Stein, MD

Blood (2015) 126 (23): 454.

https://doi.org/10.1182/blood.V126.23.454.454

Published: 2015

Journal Articles

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Anthony S. Stein, MD, Roland B. Walter, MD PhD MS, Harry P Erba, MD PhD, Amir T. Fathi, MD, Anjali S. Advani, MD, Jeffrey E Lancet, MD, Farhad Ravandi, MD, Tibor J. Kovacsovics, MD, Daniel J. DeAngelo, MD PhD, Dale Bixby, MD PhD, Stefan Faderl, MD, Anand P Jillella, MD, Megan M. O'Meara, MD, Baiteng Zhao, PhD, Eytan M Stein

Blood (2015) 126 (23): 324.

https://doi.org/10.1182/blood.V126.23.324.324

Published: 2015

Journal Articles

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Shiven B. Patel, MD, Clinton C. Mason, PhD, Martha Glenn, MD, Christian N. Paxton, PhD, Sarah T. South, PhD, Melissa H. Cessna, MD, Julie D. Asch, MD, Erin F. Cobain, MD, Dale Bixby, MD PhD, Lauren B. Smith, MD, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Joshua D. Schiffman, MD, Rodney R. Miles, MD PhD

Blood (2015) 126 (23): 1427.

https://doi.org/10.1182/blood.V126.23.1427.1427

Published: 2015

Journal Articles

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

Michael J. Mauro, Jorge E. Cortes, MD, Andreas Hochhaus, Michele Baccarani, Timothy P. Hughes, Francois Guilhot, Michael W. Deininger, Hagop M. Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, Tim Clackson, Moshe Talpaz

Blood (2014) 124 (21): 4552.

https://doi.org/10.1182/blood.V124.21.4552.4552

Published: 2014

Journal Articles

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Moshe Talpaz, Jorge E. Cortes, Hagop Kantarjian, Neil P. Shah, Dale Bixby, Ian Flinn, Thomas O'Hare, PhD, Simin Hu, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian J. Druker, Michael W. Deininger, Michael J. Mauro, MD

Blood (2014) 124 (21): 4558.

https://doi.org/10.1182/blood.V124.21.4558.4558

Published: 2014

Journal Articles

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Nagendra Mogasala, Sumana Devata, MD, Anthony Perissinotti, PharmD, Dale Bixby, MD PhD

Blood (2014) 124 (21): 2297.

https://doi.org/10.1182/blood.V124.21.2297.2297

Published: 2014

Journal Articles

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Hongxiu Li, Mark S. Kaminski, Yifeng Li, Mehmet Yildiz, Peter Ouillette, Siân Jones, Heather Fox, Kathryn Jacobi, Kamlai Saiya-Cork, Dale Bixby, Daniel Lebovic, Diane Roulston, Kerby Shedden, Michael Sabel, Lawrence Marentette, Vincent Cimmino, Alfred E. Chang, Sami N. Malek

Blood (2014) 123 (10): 1487–1498.

https://doi.org/10.1182/blood-2013-05-500264

Published: 2014

Includes: Supplemental data

Journal Articles

Recurrent STAT6 Mutations In Follicular Lymphoma

Sami Malek, MD, Mark S. Kaminski, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, PA-C, Kathryn Jacobi, NP, Kamlai Saiya-Cork, Dale Bixby, MD, PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mehmet Yildiz, MD

Blood (2013) 122 (21): 503.

https://doi.org/10.1182/blood.V122.21.503.503

Published: 2013

Journal Articles

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Sami Malek, MD, Yifeng Li, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, Kathryn Jacobi, Kamlai saiya-Cork, Dale Bixby, MD PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 147.

https://doi.org/10.1182/blood.V120.21.147.147

Published: 2012

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

Journal Articles

Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia

Meng Li, Roxane Collins, Yuchen Jiao, Peter Ouillette, Dale Bixby, Harry Erba, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Sami N. Malek

Blood (2011) 118 (22): 5914–5917.

https://doi.org/10.1182/blood-2011-05-356204

Published: 2011

Includes: Supplemental data

Journal Articles

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

Daryl Sonnichsen, David Dorer, Jorge E. Cortes, Moshe Talpaz, MD, Michael W. Deininger, MD, PhD, Neil Shah, MD, PhD, Hagop M. Kantarjian, Dale Bixby, MD PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Jeffrey Litwin, MD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD

Blood (2011) 118 (21): 4441.

https://doi.org/10.1182/blood.V118.21.4441.4441

Published: 2011

Journal Articles

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Jorge E. Cortes, Moshe Talpaz, MD, Hagop M Kantarjian, Hedy Smith, MD, PhD, Dale Bixby, MD, PhD, Usha Rafferty, MS, Mark S. Berger, MD, Scott C. Wise, MS, Tom J. Rutkoski, Ph.D, Bryan Smith, Ph.D, Richard A. Van Etten, MD PhD

Blood (2011) 118 (21): 601.

https://doi.org/10.1182/blood.V118.21.601.601

Published: 2011

Journal Articles

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

Jorge E. Cortes, Hagop M. Kantarjian, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, Simin Hu, PhD, Tim Clackson, PhD, Victor M. Rivera, PhD, Christopher D. Turner, MD, FAAP, Frank Haluska, MD, PhD, Brian J. Druker, Michael W. Deininger, Moshe Talpaz, MD

Blood (2011) 118 (21): 602.

https://doi.org/10.1182/blood.V118.21.602.602

Published: 2011

Journal Articles

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Jorge Cortes, MD, Moshe Talpaz, MD, Dale Bixby, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W. Flinn, MD, PhD, Michael Mauro, MD, Thomas O'Hare, PhD, Simin Hu, PhD, Rebecca Kan, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 210.

https://doi.org/10.1182/blood.V116.21.210.210

Published: 2010

NARROW

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Recurrent STAT6 Mutations In Follicular Lymphoma

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph + ) Leukemias Including Patients with T315I Mutation

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only